Table 4:
Parameter | Estimate | Standard Error | aOR** | 95% CI | |
---|---|---|---|---|---|
Positive Delivery UDT | 1.31 | 0.36 | 3.72 | 1.84 | 7.51 |
Positive 30d to Delivery hospitalization UDT | 0.34 | 0.34 | 1.40 | 0.73 | 2.72 |
Positive 90-31d before Delivery | 0.52 | 0.28 | 1.68 | 0.98 | 2.90 |
White non-Hispanic v. non-white race/ethnicity | −0.47 | 0.34 | 0.62 | 0.32 | 1.20 |
Public insurance v. Private/other | 0.11 | 0.49 | 1.11 | 0.43 | 2.89 |
Methadone v. Buprenorphine treatment at delivery | 0.67 | 0.25 | 1.96 | 1.20 | 3.22 |
Any psychiatric diagnosis | 0.27 | 0.27 | 1.30 | 0.77 | 2.21 |
Hepatitis C | −0.038 | 0.014 | 0.97 | 0.94 | 0.99 |
Adequate v. Intermediate/ Inadequate Prenatal Care | 0.46 | 0.26 | 1.59 | 0.95 | 2.64 |
OR, odds ratio; CI, confidence interval; UDT, urine drug test; d, days
GEE was used to account for clustering of deliveries by the same women across the study period. A binary outcome was used (0=no non-prescribed substances on toxicology testing within six months of delivery, 1=evidence of non-prescribed substances on toxicology testing within six months of delivery)
Model was adjusted for all covariates listed